Journal of General Internal Medicine

, Volume 28, Issue 11, pp 1440–1446 | Cite as

Patterns of Bone Mineral Density Testing in Men Receiving Androgen Deprivation for Prostate Cancer

Original Research

ABSTRACT

BACKGROUND

Practice guidelines recommend bone mineral density (BMD) monitoring for men on androgen deprivation therapy (ADT) for prostate cancer, but single center studies suggest this is underutilized.

OBJECTIVE

We examined determinants of BMD testing in men receiving ADT in a large population-based cohort of men with prostate cancer.

DESIGN

Retrospective cohort study.

PARTICIPANTS

We used the Surveillance, Epidemiology and End-Results (SEER)-Medicare database to identify 84,036 men with prostate cancer initiating ADT from 1996 through 2008.

MAIN MEASURES

Rates of BMD testing within the period 12 months prior to 3 months after initiation of ADT were assessed and compared to matched controls without cancer and to men with prostate cancer not receiving ADT. A logistic regression model was performed predicting use of BMD testing, adjusted for patient demographics, indications for ADT use, year of diagnosis and specialty of the physician involved in the care of the patient.

KEY RESULTS

Rates of BMD testing increased steadily over time in men receiving ADT, diverging from the control groups such that by 2008, 11.5 % of men were receiving BMD testing versus 4.4 % in men with prostate cancer not on ADT and 3.8 % in the non-cancer controls. In the logistic regression model, year of diagnosis, race/ethnicity, indications for ADT use and geographic region were significant predictors of BMD testing. Patients with only a urologist involved in their care were significantly less likely to receive BMD testing as compared to those with both a urologist and a primary care physician (PCP) (odds ratio 0.71, 95 % confidence interval 0.64–0.80).

CONCLUSIONS

There has been a sharp increase in rates of BMD testing among men receiving ADT for prostate cancer over time, beyond rates noted in contemporaneous controls. Absolute rates of BMD testing remain low, however, but are higher in men who have a PCP involved in their care.

KEY WORDS

prostate cancer osteoporosis androgen deprivation therapy bone mineral density 

REFERENCES

  1. 1.
    Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363:1822–1832.PubMedCrossRefGoogle Scholar
  2. 2.
    Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419–24.PubMedCrossRefGoogle Scholar
  3. 3.
    D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821–827.PubMedCrossRefGoogle Scholar
  4. 4.
    Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516–2527.PubMedCrossRefGoogle Scholar
  5. 5.
    Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163:181.PubMedCrossRefGoogle Scholar
  6. 6.
    Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 1999;54:607.PubMedCrossRefGoogle Scholar
  7. 7.
    Diamond T, Campbell J, Bryant C, et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Cancer. 1998;83:1561.PubMedCrossRefGoogle Scholar
  8. 8.
    Smith M, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948.PubMedCrossRefGoogle Scholar
  9. 9.
    Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2002;167:1952–1956.PubMedCrossRefGoogle Scholar
  10. 10.
    Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology. 2002;60(3 Suppl 1):79–85.PubMedCrossRefGoogle Scholar
  11. 11.
    Berruti A, Tucci M, Terrone C, Gorzegno G, Scarpa RM, Angeli A, et al. Background to and management of treatment-related bone loss in prostate cancer. Drugs Aging. 2002;19:899–910.PubMedCrossRefGoogle Scholar
  12. 12.
    Scardino P. Update: NCCN prostate cancer clinical practice guidelines. J Natl Compr Canc Netw. 2005;3(Suppl 1):S29–33.PubMedGoogle Scholar
  13. 13.
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–164.PubMedCrossRefGoogle Scholar
  14. 14.
    Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897–7903.PubMedCrossRefGoogle Scholar
  15. 15.
    http://www.nccn.org. NCCN clinical practice guidelines in oncology version 1.2013 prostate cancer. Last accessed March 4th, 2013.
  16. 16.
    Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005;103:237–241.PubMedCrossRefGoogle Scholar
  17. 17.
    Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME. Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother. 2006;40:2107–2114.PubMedCrossRefGoogle Scholar
  18. 18.
    Yee EFT, White RE, Murata GH, Handanos C, Hoffman RM. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Int Med. 2007;22:1305–1310.CrossRefGoogle Scholar
  19. 19.
    Alibhai SMH, Yun L, Cheung AM, Paszat L. Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA. 2012;307:255–256.PubMedCrossRefGoogle Scholar
  20. 20.
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(suppl IV):3–18.Google Scholar
  21. 21.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRefGoogle Scholar
  22. 22.
    Klabunde C, Potosky A, Legler J, Warren J. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258–67.PubMedCrossRefGoogle Scholar
  23. 23.
    Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458–1465.PubMedCrossRefGoogle Scholar
  24. 24.
    Smith MR, Egerdie B, Toriz NH, et al. Denusomab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–755.PubMedCrossRefGoogle Scholar
  25. 25.
    Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010;184:1316–1321.PubMedCrossRefGoogle Scholar
  26. 26.
    Ito K, Elkin EB, Girotra M, Morris MJ. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med. 2010;152:621–629.PubMedCrossRefGoogle Scholar
  27. 27.
    Shahinian VB. Prostate cancer: reducing fracture risk in men on androgen deprivation therapy. Nat Rev Urol. 2011;8:9–10.PubMedCrossRefGoogle Scholar
  28. 28.
    King AB, Fiorentino DM. Medicare payment cuts for osteoporosis testing reduced use despite tests’ benefit in reducing fractures. Health Aff. 2011;30:2362–2370.CrossRefGoogle Scholar
  29. 29.
    Curtis JR, Laster AJ, Becker DJ, et al. Regional variation in the denial of reimbursement for bone mineral density testing among US Medicare beneficiaries. J Clin Densitom. 2008;11:568–574.PubMedCrossRefGoogle Scholar
  30. 30.
    Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615–1621.PubMedCrossRefGoogle Scholar
  31. 31.
    Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21:1447–1451.PubMedCrossRefGoogle Scholar
  32. 32.
    Earle CC, Breville BA. Under use of necessary care among cancer survivors. Cancer. 2004;101:1712–1719.PubMedCrossRefGoogle Scholar
  33. 33.
    Earle CC. Failing to plan is planning to fail: improving the quality of care with survivorship care plans. J Clin Oncol. 2006;24:5112–5116.PubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2013

Authors and Affiliations

  1. 1.Department of Internal MedicineUniversity of MichiganAnn ArborUSA
  2. 2.Department of Internal MedicineUniversity of Texas Medical BranchGalvestonUSA
  3. 3.Sealy Center on AgingUniversity of Texas Medical BranchGalvestonUSA
  4. 4.Department of Preventive Medicine and Community HealthUniversity of Texas Medical BranchGalvestonUSA

Personalised recommendations